Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Issued for PfGARP Malaria Antibodies Central to Company’s Malaria Treatment and Prevention Platforms
Ocean Biomedical (NASDAQ:OCEA) announced a key U.S. patent issued for Dr. Jonathan Kurtis' groundbreaking malaria therapeutic antibody discovery targeting PfGARP. This patent expands protection for novel approaches to malaria prevention and treatment, including:
1. A powerful vaccine candidate for long-term prevention
2. A therapeutic antibody for short-term prevention
3. A small molecule drug to treat severe malaria
The patent adds to Ocean Biomedical's portfolio of over 60 patents developed through $125M in grants. This novel approach causes parasite death at a key stage in the malarial cycle, addressing growing resistance to current Artemisinin-based drugs. The company aims to develop new treatment options to combat malaria, which killed approximately 627,000 individuals in 2022.
Ocean Biomedical (NASDAQ:OCEA) ha annunciato un importante brevetto statunitense rilasciato per la scoperta innovativa di un anticorpo terapeutico contro la malaria del Dr. Jonathan Kurtis, mirato a PfGARP. Questo brevetto amplia la protezione per nuovi approcci alla prevenzione e trattamento della malaria, tra cui:
1. Un potente candidato vaccinale per la prevenzione a lungo termine
2. Un anticorpo terapeutico per la prevenzione a breve termine
3. Un farmaco a piccole molecole per trattare la malaria grave
Il brevetto si aggiunge al portafoglio di Ocean Biomedical di oltre 60 brevetti sviluppati attraverso 125 milioni di dollari in sovvenzioni. Questo approccio innovativo provoca la morte del parassita in una fase chiave del ciclo malarico, affrontando la crescente resistenza ai farmaci attuali a base di Artemisinina. L'azienda mira a sviluppare nuove opzioni di trattamento per combattere la malaria, che ha causato circa 627.000 decessi nel 2022.
Ocean Biomedical (NASDAQ:OCEA) anunció un patente clave en EE. UU. para el descubrimiento innovador del anticuerpo terapéutico contra la malaria del Dr. Jonathan Kurtis, dirigido a PfGARP. Esta patente amplía la protección para nuevos enfoques en la prevención y tratamiento de la malaria, incluyendo:
1. Un potente candidato a vacuna para la prevención a largo plazo
2. Un anticuerpo terapéutico para la prevención a corto plazo
3. Un medicamento de molécula pequeña para tratar la malaria severa
La patente se suma al portafolio de Ocean Biomedical de más de 60 patentes desarrolladas a través de 125 millones de dólares en subvenciones. Este enfoque novedoso causa la muerte del parásito en una etapa clave del ciclo de la malaria, abordando la creciente resistencia a los medicamentos actuales basados en Artemisinina. La compañía tiene como objetivo desarrollar nuevas opciones de tratamiento para combatir la malaria, que causó aproximadamente 627,000 muertes en 2022.
오션 바이오메딕시널(Ocean Biomedical, NASDAQ:OCEA)은 조나단 커티스 박사의 혁신적인 말라리아 치료 항체 발견을 위해 미국 특허가 발급되었다고 발표했습니다. 이 특허는 PfGARP를 겨냥한 것입니다. 이 특허는 말라리아 예방 및 치료를 위한 새로운 접근 방식에 대한 보호를 확대합니다. 세부 사항은 다음과 같습니다:
1. 장기 예방을 위한 강력한 백신 후보
2. 단기 예방을 위한 치료 항체
3. 중증 말라리아 치료를 위한 소분자 약물
이 특허는 1억 2500만 달러의 보조금을 통해 개발된 60개 이상의 특허로 구성된 오션 바이오메딕시널의 포트폴리오에 추가됩니다. 이 새로운 접근 방식은 말라리아 주기에서 중요한 단계에서 기생충 사멸을 유도하여 현재의 아르테미시닌 계열 약물에 대한 저항성 증가 문제를 해결합니다. 이 회사는 2022년에 약 627,000명이 사망한 말라리아를 퇴치하기 위해 새로운 치료 옵션을 개발하는 것을 목표로 합니다.
Ocean Biomedical (NASDAQ:OCEA) a annoncé un brevet clé aux États-Unis pour la découverte révolutionnaire d'anticorps thérapeutiques contre la malaria par le Dr Jonathan Kurtis, ciblant PfGARP. Ce brevet élargit la protection pour de nouvelles approches de prévention et de traitement du paludisme, comprenant :
1. Un puissant candidat vaccin pour la prévention à long terme
2. Un anticorps thérapeutique pour la prévention à court terme
3. Un médicament à petite molécule pour traiter les cas graves de paludisme
Le brevet vient s'ajouter au portefeuille de plus de 60 brevets d'Ocean Biomedical, développés grâce à 125 millions de dollars en subventions. Cette approche novatrice provoque la mort du parasite à une étape clé du cycle palustre, abordant ainsi la résistance croissante aux médicaments actuels à base d'artémisinine. L'entreprise vise à développer de nouvelles options de traitement pour lutter contre le paludisme, qui a causé environ 627 000 décès en 2022.
Ocean Biomedical (NASDAQ:OCEA) gab einen wichtigen US-Patent bekannt, das für die bahnbrechende therapeutische Antikörperentdeckung gegen Malaria von Dr. Jonathan Kurtis erteilt wurde, welche auf PfGARP abzielt. Dieses Patent erweitert den Schutz für neue Ansätze zur Prävention und Behandlung von Malaria, einschließlich:
1. Ein leistungsstarker Impfstoffkandidat für die Langzeitprävention
2. Ein therapeutischer Antikörper für die kurzfristige Prävention
3. Ein kleines Molekülmedikament zur Behandlung schwerer Malaria
Das Patent erweitert das Portfolio von Ocean Biomedical um über 60 Patente, die durch 125 Millionen US-Dollar an Zuschüssen entwickelt wurden. Dieser neuartige Ansatz führt zum Tod des Parasiten in einer Schlüsselphase des malariabedingten Zyklus und geht der wachsenden Resistenz gegen die derzeitigen artemisininbasierten Medikamente entgegen. Das Unternehmen zielt darauf ab, neue Behandlungsoptionen zu entwickeln, um Malaria zu bekämpfen, die im Jahr 2022 etwa 627.000 Menschenleben gefordert hat.
- Key U.S. patent issued for malaria therapeutic antibody discovery
- Expanded protection for three novel malaria prevention and treatment approaches
- Addition to a global patent portfolio of over 60 patents
- Novel approach addresses growing resistance to current malaria treatments
- Potential to develop a new class of anti-malarial interventions
- None.
Insights
The issuance of this patent for PfGARP malaria antibodies is a significant milestone in Ocean Biomedical's malaria research. Dr. Kurtis' discovery of the PfGARP "kill switch" mechanism represents a novel approach to combating malaria, potentially leading to a new class of antimalarial interventions. This is particularly important given the growing resistance to current Artemisinin-based drugs.
The patent strengthens Ocean Biomedical's intellectual property portfolio, covering three potential interventions: a vaccine candidate, a therapeutic antibody and a small molecule drug. These developments are timely, addressing the urgent need for new treatments as malaria parasites evolve. The company's multi-pronged approach could significantly impact both prevention and treatment strategies, potentially saving hundreds of thousands of lives annually.
This patent issuance is a positive development for Ocean Biomedical (NASDAQ:OCEA), enhancing its competitive position in the malaria treatment market. The company's expanding patent portfolio, now exceeding 60 patents, demonstrates strong R&D capabilities and potential for future revenue streams. With
Investors should note the market potential for new malaria treatments, given the disease's global impact and the limitations of current options. While commercialization timelines remain uncertain, this patent could attract partnership opportunities or licensing deals, potentially boosting the company's valuation. However, as with all biotech investments, risks remain high until products reach late-stage clinical trials or market approval.
The development of new malaria interventions by Ocean Biomedical is critically important for global health. With
The potential for a new class of antimalarial drugs is particularly exciting, given the increasing resistance to current treatments. If successful, these interventions could revolutionize malaria control efforts, especially in high-burden regions like sub-Saharan Africa. However, it's important to note that extensive clinical trials and regulatory approvals will be necessary before these solutions can reach those in need, a process that typically takes several years.
Providence, RI, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ:OCEA) announced today that its Scientific Co-founder Dr. Jonathan Kurtis, MD, PhD, has been issued a key U.S. patent for his groundbreaking malaria therapeutic antibody discovery that targets PfGARP. Since publicizing news of his original research on PfGARP and its critical role in the malaria cycle in the Journal NATURE, Dr. Kurtis and his team have been working to deepen their understanding of how it naturally triggers the death of malaria parasites, and their control of that mechanism. Their expanded insights have already led to: 1.) a powerful vaccine candidate targeted for long term prevention of malaria infection; 2.) a therapeutic antibody candidate for short term malaria prevention; and 3.) a therapeutic small molecule drug candidate targeted to treat severe malaria, with potential to launch a whole new class of malaria medicines.
This patent is adding to Ocean Biomedical’s global patent portfolio of over 5 dozen patents for discoveries with potential to impact major unmet medical needs in infectious disease, oncology, and fibrosis, developed through grants totaling over
Kurtis’ novel approach causes parasite death at a key stage in the malarial cycle, triggering programmed cell death through apoptosis. This patent expands protection for Dr. Kurtis’ novel discoveries at a time when the most common strains of malaria are showing signs of growing resistance to current Artemisinin-based drugs.
“Inducing parasite cell death via targeting PfGARP is a novel approach that has potential to result in a whole new class of anti-malarial interventions, including mRNA-based vaccines, small molecule drugs and our current monoclonal antibody,” said Dr. Kurtis. “Our monoclonal antibody and small molecule drug comes at a critical time because malaria parasites are developing resistance to current frontline therapeutics, and the currently approved vaccine offers only very limited protection.”
Dr. Jonathan Kurtis conducting research near Kisumu, Kenya, one of the world’s most malaria-infected regions
Addressing a Global Unmet Need
Malaria is the greatest single-agent killer of children on the planet, killing approximately 627,000 individuals in 2022. Artemisinin-based drug therapy remains the mainstay of treatment, but the spread of parasites resistant to this family of compounds threatens recent progress achieved by antimalarial campaigns and underscores the urgent need to identify new anti-malarial drugs.
Leadership Comments
“At each step in the process we are learning more about how this “kill switch” mechanism works to interrupt the malaria parasite’s lifecycle, and how we can exploit that on the prevention side and the treatment side,” commented Dr. Jake Kurtis, Scientific Co-founder of Ocean Biomedical, member of Ocean Biomedical’s board of directors and Chair of Pathology and Laboratory Medicine at the Warren Alpert Medical School Brown University.
“The progress we have been able to make thus far in advancing novel targets is a testament to Ocean Biomedical’s innovative model and deep partnership with premier research institutions. We are hopeful that Dr. Kurtis’ discoveries will lead to powerful new treatment options that can save hundreds of thousands of lives, and we are proud to be leading in this important work,” said Elizabeth Ng, Chief Executive Officer of Ocean Biomedical.
“The resurgence of Falciparum malaria worldwide is increasingly alarming and we are pleased to see Dr. Kurtis’ work receive this patent coverage for such an important discovery. We will work hard to accelerate the development of our novel vaccine candidate and this novel class of antimalarial antibodies to get a new treatment option for severe malaria available as soon as possible,” said Dr. Chirinjeev Kathuria, co-founder and Executive Chairman.
About Ocean Biomedical
Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most.
To learn more, visit www.oceanbiomedical.com
Forward-Looking Statements
The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, although not all forward-looking statements contain such identifying words. These forward-looking statements include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics and expectations. These statements are based on various assumptions, whether or not identified herein, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions.
The announced discoveries were based solely on laboratory and animal studies. Ocean Biomedical has not conducted any studies that show similar efficacy or safety in humans. There can be no assurances that this treatment will prove safe or effective in humans, and that any clinical benefits of this treatment is subject to clinical trials and ultimate approval of its use in patients by the FDA. Such approval, if granted, could be years away.
Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of the Company that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include (i) the outcome of any legal proceedings that may be instituted against the Company; (ii) changes in the markets in which the Company competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (iii) changes in domestic and global general economic conditions; (iv) risk that the Company may not be able to execute its growth strategies; (v) risks related to the ongoing COVID-19 pandemic and response, including supply chain disruptions; (vi) risk that the Company may not be able to develop and maintain effective internal controls; (vii) the risk that the Company may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (viii) the ability to develop, license or acquire new therapeutics; (ix) the risk that the Company will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (x) the risk that the Company experiences difficulties in managing its growth and expanding operations; (xi) the risk of product liability or regulatory lawsuits or proceedings relating to the Company’s business; (xii) the risk of cyber security or foreign exchange losses; (xiii) the risk that the Company is unable to secure or protect its intellectual property.
The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, and which are described in the “Risk Factors” section of the Company’s definitive proxy statement filed by the Company on January 12, 2023, and other documents to be filed by the Company from time to time with the SEC and which are and will be available at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements. These forward-looking statements should not be relied upon as representing the Company’s assessments as of any date subsequent to the date of this filing. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Ocean Biomedical Investor Relations info@oceanbiomedical.com
Ocean Biomedical Media Relations connect@oceanbiomedical.com
Attachments
FAQ
What is the significance of Ocean Biomedical's new patent for malaria treatment?
How many patents does Ocean Biomedical (NASDAQ: OCEA) now hold?
What are the three main approaches Ocean Biomedical (NASDAQ: OCEA) is developing for malaria?
How does Ocean Biomedical's (NASDAQ: OCEA) malaria treatment approach differ from current methods?
